Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | PIM1 | P11309 | 9/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24073261 | 0.89 | HDAC1 (0.49) | HDAC1HDAC6PIM1USP30PIM2 | |
| SCHEMBL30370264 | 0.89 | HDAC1 (0.49) | HDAC1HDAC6PIM1USP30PIM2 | |
| SCHEMBL30061997 | 0.89 | HDAC1 (0.41) | HDAC1HDAC6PIM1USP30SLC5A1 | |
| SCHEMBL30062624 | 0.89 | HDAC1 (0.41) | HDAC1HDAC6PIM1USP30SLC5A1 | |
| SCHEMBL29268973 | 0.85 | HDAC1 (0.37) | HDAC1HDAC6PIM1PIM2SLC5A1 | |
| SCHEMBL30474032 | 0.85 | HDAC1 (0.37) | HDAC1HDAC6PIM1PIM2SLC5A1 | |
| SCHEMBL29268975 | 0.85 | HDAC1 (0.37) | HDAC1HDAC6PIM1PIM2SLC5A1 | |
| SCHEMBL30473969 | 0.85 | HDAC1 (0.37) | HDAC1HDAC6PIM1PIM2SLC5A1 | |
| SCHEMBL22585734 | 0.85 | FAAH (0.43) | HDAC1HDAC6USP30 | |
| SCHEMBL25144570 | 0.85 | USP30 (0.42) | HDAC1HDAC6PIM1USP30TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119013-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| EP-4132925-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| CN-115461340-A | N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2022-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119013-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP28, USP47 | HDAC1 517/4885HDAC6 633/4885PIM1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.